Drug Details
General Information of the Drug (ID: DR1499) | ||||
---|---|---|---|---|
Name |
Laninamivir
|
|||
Synonyms |
Laninamivir; 203120-17-6; UNII-B408IW3GL5; R-125489; Laninamivir (CS-8958); B408IW3GL5; (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 5-(Acetylamino)-2,6-Anhydro-4-Carbamimidamido-3,4,5-Trideoxy-7-O-Methyl-D-Glycero-D-Galacto-Non-2-Enonic Acid; Laninamivir [INN:JAN]; Laninamivir (INN); LANI; R 125489; CHEMBL466246; SCHEMBL12284832; DTXSID60942457; BCPP000190; C13H22N4O7; BCP27633; EX-A4019; ZINC3985629; BDBM50009296; AKOS015850995; AKOS032947260; BCP9000836; DB12791; (2R,3R,4S)-3-acetamido-2-[(1R,2R)-2,3-dihydroxy-1-methoxy-propyl]-4-guanidino-3,4-dihydro-2H-pyran-6-carboxylic acid; HY-14818; CS-0003575; Y0284; C21557; D09410; S-7726; 120L176; A814430; Q6487096; (2R,3R,4S)-3-acetamido-4-[bis(azanyl)methylideneamino]-2-[(1R,2R)-1-methoxy-2,3-bis(oxidanyl)propyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; (4S,5R,6R)-5-acetamido-4-carbamimidamido-6-((1R,2R)-3-hydroxy-2-methoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid; 2,6-Anhydro-4-carbamimidamido-3,4,5-trideoxy-5-[(1-hydroxyethylidene)amino]-7-O-methylnon-2-enonic acid; 5-acetamido-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-non-2-enonic acid; 5-Acetylamino-4-(diaminomethyl-amino)-6-(2,3-dihydroxy-1-methoxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Influenza [ICD-11: 1E30] | Phase 2 | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C13H22N4O7
|
|||
PubChem CID | ||||
Canonical SMILES |
CC(=O)NC1C(C=C(OC1C(C(CO)O)OC)C(=O)O)N=C(N)N
|
|||
InChI |
1S/C13H22N4O7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20H,4H2,1-2H3,(H,16,19)(H,21,22)(H4,14,15,17)/t6-,7+,9+,10+,11+/m0/s1
|
|||
InChIKey |
QNRRHYPPQFELSF-CNYIRLTGSA-N
|
|||
CAS Number |
CAS 203120-17-6
|
|||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Methylglyoxal | Saccharomyces cerevisiae | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | MDCK | CVCL_0422 | Healthy | Canis lupus familiaris | ||
Experimental
Result(s) |
MGO has potent inhibitory activity against influenza viruses and also enhanced the effect of NA inhibitors. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Proteasome alpha 1 (PSMA1) | Molecule Info | [3] | |
Proteasome alpha 2 (PSMA2) | Molecule Info | [3] | ||
Proteasome alpha 3 (PSMA3) | Molecule Info | [3] |